Zobrazeno 1 - 10
of 135
pro vyhledávání: '"Lorna Rodriguez-Rodriguez"'
Autor:
Lorna Rodriguez-Rodriguez, Rui Huang, Mihaela Cristea, Qianqian Zhao, Adrian Kohut, Hua Yu, Mihae Song, Antons Martincuks, Chunyan Zhang, Edward W Wang, Theresa Austria, Yi-Jia Li, Nicole Lugo Santiago, Rosemarie Martinez Borrero, Binghui Shen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Background Ovarian cancer is the most lethal gynecological malignancy, with limited treatment options after failure of standard therapies. Despite the potential of poly(ADP-ribose) polymerase inhibitors in treating DNA damage response (DDR)-deficient
Externí odkaz:
https://doaj.org/article/29ce33204b0e45249cb86e478b123daa
Autor:
Eric Hee Jun Lee, John P. Murad, Lea Christian, Jackson Gibson, Yukiko Yamaguchi, Cody Cullen, Diana Gumber, Anthony K. Park, Cari Young, Isabel Monroy, Jason Yang, Lawrence A. Stern, Lauren N. Adkins, Gaurav Dhapola, Brenna Gittins, Wen-Chung Chang, Catalina Martinez, Yanghee Woo, Mihaela Cristea, Lorna Rodriguez-Rodriguez, Jun Ishihara, John K. Lee, Stephen J. Forman, Leo D. Wang, Saul J. Priceman
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)
Abstract Chimeric antigen receptor (CAR) T cell therapeutic responses are hampered by limited T cell trafficking, persistence, and durable anti-tumor activity in solid tumors. However, these challenges can be largely overcome by relatively unconstrai
Externí odkaz:
https://doaj.org/article/211ce127e82c40c7b1c8f149a15dcd09
Autor:
Christina H. Wei, Edward Wang, Evita Sadimin, Lorna Rodriguez-Rodriguez, Mark Agulnik, Janet Yoon, Janine LoBello, Szabolcs Szelinger, Clarke Anderson
Publikováno v:
Gynecologic Oncology Reports, Vol 50, Iss , Pp 101294- (2023)
Externí odkaz:
https://doaj.org/article/d87174b9f16a4304bc0bd2d48e0addbb
Autor:
Christina H Wei, Susan Shehayeb, Nicole Lugo Santiago, Laura Kruper, Ernest Han, Edward Wang, Mihaela Cristea, Lorna Rodriguez-Rodriguez, Susan E Yost, Daphne Stewart
Publikováno v:
PLoS ONE, Vol 18, Iss 6, p e0286998 (2023)
Histologic and genetic mutation information from racially and ethnically diverse populations is warranted to better inform future cancer predisposition and promote health equity. A single institutional, retrospective capture of patients with gynecolo
Externí odkaz:
https://doaj.org/article/0ddad5e697aa4134a687fd18945408e2
Autor:
Qianqian Zhao, Adrian Kohut, Yi-Jia Li, Antons Martincuks, Theresa Austria, Chunyan Zhang, Nicole Lugo Santiago, Rosemarie Martinez Borrero, Xuan Thuy Phan, Laleh Melstrom, Lorna Rodriguez-Rodriguez, Hua Yu
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Recently, poly(ADP-ribosyl)ation polymerase inhibitors (PARPis), which induce synthetic lethality of tumor cells with DNA damage repair defects, have emerged as a promising therapy for ovarian, breast, and pancreatic cancer. Although the PARPi Olapar
Externí odkaz:
https://doaj.org/article/39c14fa5669444e889ed0d1e0d5c327b
Autor:
Elan Gorshein, Kant Matsuda, Gregory Riedlinger, Levi Sokol, Lorna Rodriguez-Rodriguez, Firas Eladoumikdachi, Miral Grandhi, Shridar Ganesan, Deborah L. Toppmeyer, Lindsay Potdevin, Kathleen Toomey, Kim M. Hirshfield, Nancy Chan
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 2, Pp 931-937 (2021)
Metaplastic breast cancer (MBC) is a rare and aggressive subtype of breast cancer. Tumor characteristics typically feature estrogen receptor, progesterone receptor, and HER2-negative, triple-negative breast cancer (TNBC), with a poorer prognosis rela
Externí odkaz:
https://doaj.org/article/bdb6ea84938e4385b44989b9ca95f57f
Autor:
Antons Martincuks, Jieun Song, Adrian Kohut, Chunyan Zhang, Yi-Jia Li, Qianqian Zhao, Edward Mak, Lorna Rodriguez-Rodriguez, Hua Yu, Mihaela Cristea
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Despite the promising activity of poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) in many cancer types with defects in the DNA damage response the majority of the treated patients acquire PARPi resistance and succumb to their diseases. Conseque
Externí odkaz:
https://doaj.org/article/5021de688e324a6394b97709ac61908c
Autor:
Bhavna S. Paratala, Jon H. Chung, Casey B. Williams, Bahar Yilmazel, Whitney Petrosky, Kirstin Williams, Alexa B. Schrock, Laurie M. Gay, Ellen Lee, Sonia C. Dolfi, Kien Pham, Stephanie Lin, Ming Yao, Atul Kulkarni, Frances DiClemente, Chen Liu, Lorna Rodriguez-Rodriguez, Shridar Ganesan, Jeffrey S. Ross, Siraj M. Ali, Brian Leyland-Jones, Kim M. Hirshfield
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
Fusions of the gene RET have been described in thyroid and lung cancers. Here, the AUs identify RET gene alterations, including known fusions, novel fusions, and rearrangements in breast cancer (BC) that are involved in the tumorigenic process and sh
Externí odkaz:
https://doaj.org/article/af4ef9c2d18542d6986221a4da000c4e
Autor:
Antons Martincuks, Pei-Chuan Li, Qianqian Zhao, Chunyan Zhang, Yi-Jia Li, Hua Yu, Lorna Rodriguez-Rodriguez
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Despite significant progress in cancer therapy over the last decades, ovarian cancer remains the most lethal gynecologic malignancy worldwide with the five-year overall survival rate less than 30% due to frequent disease recurrence and chemoresistanc
Externí odkaz:
https://doaj.org/article/96062329de784f1daec48555a07d0af9
Autor:
Er Yue, Guangchao Yang, Yuanfei Yao, Guangyu Wang, Atish Mohanty, Fang Fan, Ling Zhao, Yanqiao Zhang, Tamara Mirzapoiazova, Tonya C. Walser, Lorna Rodriguez-Rodriguez, Yuman Fong, Ravi Salgia, Edward Wenge Wang
Publikováno v:
Cancers, Vol 13, Iss 17, p 4265 (2021)
CA-125, encoded by the MUC16 gene, is highly expressed in most ovarian cancer cells and thus serves as a tumor marker for monitoring disease progression or treatment response in ovarian cancer patients. However, targeting MUC16/CA-125 for ovarian can
Externí odkaz:
https://doaj.org/article/662de94b912f47ca91abbdf54ed87ea7